[Featured Stock] FutureChem Rises Over 14% on 'Expectations for Innovative Prostate Cancer Treatment'

The stock price of FutureChem, which recently applied for phase 3 clinical trials of a prostate cancer treatment, is showing strong performance.

As of 10:26 AM on the 14th, FutureChem was trading at 26,000 KRW, up 3,300 KRW (14.54%) compared to the previous trading day.

Earlier, on the 10th, FutureChem applied for phase 3 clinical trials of the prostate cancer treatment FC705. The trials will be conducted in combination with the standard hormone therapy, not as a monotherapy.

On the same day, Minyong Eom, a research fellow at Shinhan Investment Corp., explained, "The design of FutureChem's phase 3 clinical trial aims to expand the use of radiopharmaceuticals as an initial treatment for prostate cancer," adding, "It also reflects the judgment of the company and medical staff that FC705 could change the treatment guidelines for prostate cancer."

The current phase 3 clinical trial of FC705 for metastatic castration-resistant prostate cancer (mCRPC) is being conducted with the goal of replacing the existing second-line chemotherapy treatments (docetaxel, cabazitaxel) by combining the standard hormone therapy with FC705. Research fellow Eom stated, "Various imaging evaluations are also important, and the trial applies the global standard techniques as well as the world's most precise diagnostic method developed in-house using FC303."

He added, "The phase 2 clinical trial results of FC705 show higher figures compared to competitors' phase 3 trials as well as other phase 2 results," and noted, "If superior results are announced, it could be considered undervalued."

This content was produced with the assistance of AI translation services.